NCT05291546View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

April 2, 2024

Study Completion Date

April 2, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

REGN9035

Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22.

DRUG

REGN5381

Part B: Selected doses administered by IV infusion on day 1.

OTHER

Placebo

Part A: Single dose administered by IV infusion on day1. Part B: Single dose administered by IV infusion on day 1, day 2 and/or day 22.

Trial Locations (2)

10117

Charite Research Organisation GmbH, Berlin

B-3000

Universitair Ziekenhuis Leuven Gasthuisberg Campus, Leuven

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY